AbCellera CEO Carl Hansen Points to ABCL635 as First Proof of Antibody Platform at Stifel Conference

AbCellera CEO Carl Hansen presented at Stifel's 2026 Healthcare Conference on November 10, 2026, and called ABCL635 the first evidence of the company's antibody platform. The Phase II data for ABCL635, reported in August, compared efficacy and safety to standard-of-care oral small molecules, according to Seeking Alpha.

Hansen Pitches ABCL635 Data to Stifel Audience

Hansen opened the session by describing AbCellera as a Vancouver biotech that has built a platform for developing antibody medicines. He said the company has "a very significant competitive advantage in solving some difficult problems" and that its mission is to repeatedly invent, develop and commercialize breakthrough medicines. Hansen said AbCellera has made a transition recently and that ABCL635 is the first evidence of that shift.

Stifel analyst Stephen Willey, who introduced Hansen on day two of the conference, said the Phase II data reported in August "took a lot of us by surprise in a very good way." Willey asked Hansen to walk through the high points of the data and how the efficacy and safety metrics compare to standard-of-care oral small molecules on the market. Stifel Financial is the host of the conference where Hansen spoke.

AbCellera's Funding and Partnership Record

AbCellera has started more than 100 antibody drug programs with over 40 partners, and 16 candidates have reached the clinic since 2015 through partnerships and internal development, according to akta.pro company records. The same records show the company has raised 11 funding rounds, including a $200 million post-IPO equity round in August 2026, and held approximately $700 million in available liquidity at the end of 2025. In June 2026, AbCellera entered a preclinical research collaboration, option and license agreement with Jazz Pharmaceuticals for T-cell engaging multispecific antibodies in gastrointestinal cancers and solid tumors, with $56 million upfront and up to $792 million per program in potential milestones plus tiered royalties.

OX40 Exit and Earlier Conference Plans

AbCellera abandoned its OX40 antibody ABCL575 after a Phase 1 study showed favorable tolerability and pharmacokinetics, citing external developments in the OX40 class, FierceBiotech reported on November 10, 2026. The decision followed Kyowa Kirin's shutdown of rocatinlimab studies and Sanofi's cancellation of amlitelimab. On October 22, 2026, Stock Titan reported that AbCellera had announced presentations at the Stifel Healthcare Conference on November 11, 2026, and the Jefferies Global Healthcare Conference in London on November 16, 2026.

Upcoming AbCellera Presentations

AbCellera said it will present at the UBS Global Biopharma Conference on November 17, 2026, with a live audio webcast and replay available through its Investor Relations website, Business Wire Blog reported on November 5, 2026.